KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) FCF Margin (2016 - 2025)

NovoCure's FCF Margin history spans 12 years, with the latest figure at 13.13% for Q4 2025.

  • For Q4 2025, FCF Margin fell 545.0% year-over-year to 13.13%; the TTM value through Dec 2025 reached 11.55%, down 11.0%, while the annual FY2025 figure was 11.55%, 11.0% down from the prior year.
  • FCF Margin for Q4 2025 was 13.13% at NovoCure, down from 8.92% in the prior quarter.
  • Across five years, FCF Margin topped out at 17.64% in Q2 2021 and bottomed at 31.3% in Q1 2024.
  • The 5-year median for FCF Margin is 7.79% (2022), against an average of 6.2%.
  • The largest annual shift saw FCF Margin plummeted -3363bps in 2023 before it surged 2067bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 0.1% in 2021, then tumbled by -8189bps to 7.89% in 2022, then crashed by -102bps to 15.98% in 2023, then soared by 52bps to 7.68% in 2024, then crashed by -71bps to 13.13% in 2025.
  • Per Business Quant, the three most recent readings for NVCR's FCF Margin are 13.13% (Q4 2025), 8.92% (Q3 2025), and 13.49% (Q2 2025).